Howard, Frederick M. http://orcid.org/0000-0002-6039-1141
Pearson, Alexander T. http://orcid.org/0000-0003-2801-7456
Nanda, Rita http://orcid.org/0000-0001-5248-0876
Funding for this research was provided by:
National Institutes of Health (F32-CA265232)
national institutes of health (K08-DE026500, U01-CA243075)
Article History
Received: 24 June 2021
Accepted: 23 June 2022
First Online: 14 July 2022
Declarations
:
: FMH: no disclosures, RN: Aduro, Cardinal Health, Clovis, Fujifilm, G1 Therapeutics, Genentech, Immunomedics/Gilead, Ionis, iTeos, MacroGenics, Merck, Oncosec, Pfizer, Seattle Genetics. Data Safety Monitoring Board: G1 Therapeutics. Research Funding: Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics/Gilead, Merck, OBI Pharma, Odonate Therapeutics, OncoSec, Pfizer, Seattle Genetics, Taiho. ATP: Advisory board for Prelude Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.